Groww Logo
search
Home>IPO>Glenmark Life Sciences Ltd.

Glenmark Life Sciences IPO

Glenmark Life Sciences Ltd.

₹13,900 /20 sharesMinimum Investment

IPO Listing Details

Listed OnIssue PriceListing PriceListing Gains
BSE & NSE₹720₹750+₹30.00 (4.17%)

IPO Details

Bidding DatesMin. InvestmentLot SizePrice Range
27 Jul ‘21 - 29 Jul ‘21₹13,90020₹695 - ₹720
Issue SizeIPO Doc
1513.6Cr
RHP PDFopen_in_new

Subscription Rate As on 29th Jul 2021, 5:00 PM

  • Retail Individual Investor
    14.63x
  • Non-Institutional Investor
    122.54x
  • Qualified Institutional Buyers
    36.97x

About Company

Glenmark Life Sciences Ltd., a subsidiary of Glenmark Pharmaceuticals Ltd., is a leading developer and manufacturer of select high-value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes. It also manufactures and sells APIs for gastro-intestinal disorders, anti-infectives, and other therapeutic areas.
... Read More
Parent Organisation
Glenmark Life Sciences Ltd.
Founded
2011
Managing Director
Yasir Rawjee
Glenmark Life Sciences IPO review - Glenmark Life Sciences IPO details, business, financials

Strengths & Risks

  • add
    Leading developer and manufacturer of select high value, non-commoditized APIs in chronic therapeutic areas
  • add
    Strong relationships with leading global generic pharmaceutical companies
  • add
    Quality-focused and has compliant manufacturing and R&D infrastructure
  • add
    Focused on sustainability in its operations through meaningful interventions in environment management, safety initiatives in its operations, and the occupational health of its workforce.
  • add
    Glenmark strives to achieve cost leadership across many of its products through the careful application of operations initiatives, sourcing initiatives, and R&D initiatives
  • add
    Experienced Promoters with a strong management team
  • remove
    Regulatory action due to a manufacturing or quality control problem
  • remove
    Dependency on a limited number of key customers for a significant portion of its revenues
  • remove
    Generates a significant portion of its total revenue from its API business from the sale of products in a limited number of principal therapeutic categories
  • remove
    Manufacturing and R&D facilities are located in two states and any disruption in these states can cause manufacturing to stop
  • remove
    Delay, interruption, or reduction in the supply of raw materials can harm operations
  • remove
    Impact of COVID-19
  • remove
    Significant working capital requirements for its manufacturing operations and development of new products
  • remove
    The brand name ‘Glenmark’ and the trademarks for the name ‘Glenmark Life Sciences’ and logo are registered in the name of the promoter of the company
  • remove
    Impact of pricing pressure from customers on gross margin, profitability and the company’s ability to increase the prices
  • remove
    The company has to obtain and maintain a number of statutory and regulatory licenses, permits and approvals for carrying out business including consents to establish and operate under environmental laws
  • remove
    Exposure to counterparty credit risk
  • remove
    Inability to accurately forecast demand for its products and manage inventory accordingly

Financials

*All values are in Rs. Cr
No Graph Data To Display
ⓒ 2016-2021 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 1.9.7
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES: ICICI PRUDENTIAL  | HDFC  | NIPPON INDIA  | ADITYA BIRLA SUN LIFE  | SBI  | UTI  | FRANKLIN TEMPLETON  | KOTAK MAHINDRA  | IDFC  | DSP  | AXIS  | TATA  | L&T  | SUNDARAM  | PGIM  | INVESCO  | LIC  | JM FINANCIAL  | BARODA PIONEER  | CANARA ROBECO  | HSBC  | IDBI  | INDIABULLS  | MOTILAL OSWAL  | BNP PARIBAS  | MIRAE ASSET  | PRINCIPAL  | BOI AXA  | UNION KBC  | TAURUS  | EDELWEISS  | NAVI  | MAHINDRA  | QUANTUM  | PPFAS  | IIFL  | Quant  | SHRIRAM  | SAHARA | ITI
ABOUT GROWW
keyboard_arrow_down
arrow_drop_down_circle